Target Information
Direct Healthcare Group (DHG) is a comprehensive developer and manufacturer of innovative pressure care products aimed at preventing medical complications such as pressure sores, which can escalate into severe, life-threatening conditions. Established in 2009, DHG collaborates with care providers in over 20 countries across Europe and internationally, gaining recognition as a leader in pressure care technologies. The organization has been honored with the esteemed Queen’s Award for Enterprise in Innovation.
Industry Overview
The healthcare sector across Europe has witnessed significant advancements and is characterized by an increasing focus on innovative medical technologies. With the aging population and rising healthcare needs, pressure care solutions have become crucial in mitigating common health issues faced by patients in care settings. The demand for effective pressure care products is surging due to the prevalence of pressure sores, particularly among immobilized individuals.
Furthermore, the European healthcare market is progressively prioritizing patient-centered approaches, prompting care providers to seek advanced solutions that enhance patient outcomes. The integration of technological advancements into healthcare solutions is reshaping the industry landscape, leading to increased investments and collaborations among firms, particularly in pressure care.
Notably, the healthcare industry is also witnessing a rise in consolidation through mergers and acquisitions. Companies like DHG, which employ a buy-and-build strategy, are well-positioned to leverage existing market opportunities and expand their service offerings, thus enhancing competitive advantages.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Rationale Behind the Deal
The recent secondary buyout of DHG by ArchiMed marks a strategic move to capitalize on the company's impressive growth trajectory and market potential. NorthEdge, the previous investor, achieved a remarkable 3x return on its initial investment and a 39% internal rate of return (IRR) by implementing a robust growth strategy that included multiple bolt-on acquisitions and an expansion of the product range.
Recognizing the burgeoning opportunities within the European healthcare market, DHG’s acquisition by ArchiMed, a specialist in healthcare investment, aligns perfectly with its ambition to further penetrate this market while sustaining innovation and growth.
Information About the Investor
ArchiMed is a European healthcare-focused investment firm known for its strategic investments in the medical technology and services sector. The firm specializes in supporting companies like DHG that exhibit considerable growth potential in the healthcare landscape. ArchiMed's extensive international footprint and deep industry knowledge position it as an ideal partner to facilitate DHG’s aspirations of geographic and product expansion.
With a strong track record in fostering innovation and value creation within healthcare companies, ArchiMed is set to support DHG in enhancing its market presence while simultaneously catering to the evolving needs of the healthcare sector across regions.
View of Dealert
The transaction involving DHG and ArchiMed is positioned as a significant strategic investment. It reflects NorthEdge’s successful management of DHG, evidenced by the company doubling its revenue and tripling its EBITDA during their ownership. This robust performance lays a strong foundation for ArchiMed to build upon and validate its investment thesis.
The decision to pursue a specialized healthcare investor like ArchiMed is advantageous, as it introduces a partner equipped with valuable insights and networks necessary for navigating the complexities of the European market. Furthermore, the anticipated growth within the European healthcare space presents a timely and lucrative opportunity for DHG’s continued evolution.
Moreover, by leveraging ArchiMed’s expertise and strategic guidance, DHG is poised to expedite its expansion efforts and enhance its innovative product offerings. This partnership could indeed amplify DHG's impact in the healthcare sector, capturing growth prospects that align with their strategic vision.
Similar Deals
Bay Tree Private Equity → ABL Health
2023
MidEuropa → Optegra Eye Health Care
2022
Bridgepoint Development Capital → Prescient Healthcare Group
2021
AddLife AB → Healthcare 21 Group
2021
Growth Lending → A & R Care Limited
2025
ArchiMed
invested in
Direct Healthcare Group
in
in a Secondary Buyout deal